254 related articles for article (PubMed ID: 23930754)
1. Targeted therapy for NSCLC with driver mutations.
Minuti G; D'Incecco A; Cappuzzo F
Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
[TBL] [Abstract][Full Text] [Related]
2. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
3. Emerging protein kinase inhibitors for non-small cell lung cancer.
Liu SV; Subramaniam D; Cyriac GC; Abdul-Khalek FJ; Giaccone G
Expert Opin Emerg Drugs; 2014 Mar; 19(1):51-65. PubMed ID: 24354593
[TBL] [Abstract][Full Text] [Related]
4. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy in nonsmall cell lung cancer.
Puri T
Indian J Cancer; 2017; 54(1):83-88. PubMed ID: 29199670
[TBL] [Abstract][Full Text] [Related]
6. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
Vari S; Pilotto S; Maugeri-SaccĂ M; Ciuffreda L; Cesta Incani U; Falcone I; Del Curatolo A; Ceribelli A; Gelibter A; De Maria R; Tortora G; Cognetti F; Bria E; Milella M
Expert Opin Drug Discov; 2013 Nov; 8(11):1381-97. PubMed ID: 24088065
[TBL] [Abstract][Full Text] [Related]
7. Rare mutations in non-small-cell lung cancer.
D'Arcangelo M; D'Incecco A; Cappuzzo F
Future Oncol; 2013 May; 9(5):699-711. PubMed ID: 23647298
[TBL] [Abstract][Full Text] [Related]
8. Emerging targeted therapies in non-small cell lung cancer.
Khanal N; Ganti AK
Expert Rev Anticancer Ther; 2016; 16(2):177-87. PubMed ID: 26618563
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Reungwetwattana T; Weroha SJ; Molina JR
Clin Lung Cancer; 2012 Jul; 13(4):252-66. PubMed ID: 22154278
[TBL] [Abstract][Full Text] [Related]
10. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
11. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer.
Cheng L; Zhang S; Alexander R; Yao Y; MacLennan GT; Pan CX; Huang J; Wang M; Montironi R; Lopez-Beltran A
Future Oncol; 2011 Apr; 7(4):519-41. PubMed ID: 21463141
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib in the treatment of non-small-cell lung cancer.
Forde PM; Rudin CM
Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
[TBL] [Abstract][Full Text] [Related]
13. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
D'Arcangelo M; Wynes MW; Hirsch FR
Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
[TBL] [Abstract][Full Text] [Related]
14. New Targets in Non-Small Cell Lung Cancer.
Park SJ; More S; Murtuza A; Woodward BD; Husain H
Hematol Oncol Clin North Am; 2017 Feb; 31(1):113-129. PubMed ID: 27912827
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
Genova C; Rossi G; Tagliamento M; Rijavec E; Biello F; Cerbone L; Zullo L; Grossi F
Expert Rev Respir Med; 2020 Apr; 14(4):367-383. PubMed ID: 31917616
[No Abstract] [Full Text] [Related]
16. The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.
Rossi G; Graziano P; Leone A; Migaldi M; Califano R
Semin Diagn Pathol; 2013 Nov; 30(4):298-312. PubMed ID: 24342286
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
18. [Molecular profiling of non-small cell lung cancer].
Gibault L; Cazes A; Narjoz C; Blons H
Rev Pneumol Clin; 2014; 70(1-2):47-62. PubMed ID: 24566035
[TBL] [Abstract][Full Text] [Related]
19. First-line therapy of mutated non-small cell lung cancer: an update.
Stöhlmacher-Williams J
Onkologie; 2012; 35(5):293-9. PubMed ID: 22868512
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
Tan AC; Tan DSW
J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]